GLP1R and metabolic dysfunction-associated steatohepatitis: On the other hand, concerning GLP-1 RAs’ ability to improve the levels of fibrosis and to intercept with steatosis evolution to NASH and cirrhosis, prospective randomized control trials are still needed [206].